Conclusion of a non-exclusive rebate agreement pursuant to § 130a (8) SGB V for the active ingredient fremanezumab, ATC N02CD03 for the period 01.07.2025 - 30.06.2027
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Fremanezumab, ATC N02CD03 für die Zeit 01.07.2025 - 30.06.2027
Germany
Contract
BuyerDAK-Gesundheit
TypeSupplies
Estimated valuevalue not published
Published20 May 2025
CategoryMedical equipment & pharma · CPV 33000000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Abacus Medicine A/S · Kopenhagen | 172 | 2022–2026 |
| kohlpharma GmbH · Merzig | 157 | 2022–2026 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 126 | 2022–2026 |
| CC Pharma GmbH · Densborn | 121 | 2022–2025 |
| Orifarm GmbH · Leverkusen | 113 | 2015–2025 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
2019260
2020167
2021201
2022187
2023291
2024654
20251,183
20259
2026739
Who knows the rhythm prepares instead of reacting.
259
days until the deadline — Wednesday 5 May at 10:00
How to bid
Read the full notice — Original + documents
Goes directly to this tender on Vergabemarktplatz (cosinex). The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →